A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Eli Lilly
365 trials monitored
See 16 trials at risk
Diabetes
5,109 trials monitored
See 234 trials at risk
Obesity
3,894 trials monitored
See 161 trials at risk
Type 2 Diabetes
2,240 trials monitored
See 113 trials at risk
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Trial Details
NCT Number NCT07881887
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Obesity, Overweight, Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 617 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov